Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C5541010 - PF-07976016 in Adults With Obesity
2024-513679-42-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing PF-07976016 + liraglutide with Placebo + liraglutide (2 arms). Primary endpoint: Percent change from baseline in body weight at Week 16. Started Mar 2025; status: completed.
02
Drugs
PF-07976016
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2024-513679-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513679-42-00.